Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug130 | ARCT-021 Dose Regimen 2 Wiki | 1.00 |
| drug127 | ARCT-021 Dose 3 Wiki | 1.00 |
| drug128 | ARCT-021 Dose 4 Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
Determine safety and tolerability and immungenicity of investigational vaccine ARCT-021 in healthy adult volunteers.
Description: Safety and tolerability of ARCT-021 assessed by determining the incidence, severity and dose-relationship of AEs by dose
Measure: Incidence, severity and dose-relationship of AEs Time: 56 daysDescription: SARS-CoV-2-specific serum neutralizing antibody levels, expressed as GMT
Measure: Geometric mean titre for SARS-CoV-2-specific serum neutralizing antibody Time: Up to 56 daysDescription: SARS-CoV-2-specific serum neutralizing antibody levels, expressed as mean titer
Measure: Mean titre for SARS-CoV-2-specific serum neutralizing antibody levels Time: Up to 56 daysDescription: GMFR in titre for SARS-CoV-2-spike protein specific neutralizing antibodies from before vaccination to each subsequent time point
Measure: Geometric mean fold rise in titre for SARS-CoV-2-spike protein specific neutralizing antibody levels Time: Up to 56 daysDescription: GMFR in SARS-CoV-2--spike protein-specific binding antibody levels from before vaccination to each subsequent time point
Measure: Increase in SARS-CoV-2--spike protein-specific binding antibody levels Time: Up to 56 daysDescription: GMT for SARS-CoV-2--spike protein-specific binding antibody levels
Measure: Geometric mean SARS-CoV-2--spike protein-specific binding antibody titre Time: Up to 56 daysDescription: Mean titer for SARS-CoV-2--spike protein-specific binding antibody levels
Measure: Mean SARS-CoV-2--spike protein-specific binding antibody titre Time: Up to 56 daysDescription: Proportion of participants that are seronegative before vaccination achieving a titer of greater than or equal to 20 for SARS-CoV-2-specific serum neutralizing antibodies
Measure: SARS-CoV-2-specific serum neutralizing antibody seroconversion rate Time: 56 daysDescription: Proportion of participants that are seropositive before vaccination achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2-specific serum neutralizing antibody levels
Measure: SARS-CoV-2-specific serum neutralizing antibody seroconversion rate (seropositive baseline) Time: 56 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports